HLB-0532247

HLB-0532247 (0.1-1.0 mM) potently reduces Zika virus levels by more than 1 log₁₀ pfu/mL at a concentration of 0.1 mM in HUH7 and HUH7.5 cells after 4 days, while it shows weak activity in Vero cells^[1].
HLB-0532247 (1.0 mM) potently reduces West Nile virus levels by more than 4 log₁₀ pfu/mL in HUH7 and HUH7.5 cells, but shows no activity in Vero cells^[1].
HLB-0532247 (1.0 mM; 2-5 days) shows no cytotoxicity in Vero and HUH7 cells after 2 days of treatment, and only exhibits mild toxicity (cell viability >60%) after 5 days of treatment at 1.0 mM, with its CC₅₀ greater than 1 mM^[1].
HLB-0532247 (2 μM; 0-120 min) is stable in plasma, with a remaining proportion of >87% after incubation at 37°C for 2 hours^[1].
HLB-0532247 (2 μM; 0-360 min) shows stable properties in simulated gastric fluid, with approximately 76% remaining after incubation at 37°C for 6 hours^[1].
HLB-0532247 (2-10 μM; 2 h) exhibits a mean apparent permeability coefficient of 0.3 nm/sec in Caco-2 cells, showing cellular permeability similar to that of sofosbuvir^[1].
HLB-0532247 (100 μM; 24 h) is metabolized to ddhCTP in HUH7 cells. After treatment with 100 μM for 24 h, 3.8 nmol of ddhCTP is produced per 5×10⁶ cells (intracellular concentration >1 mM), representing a 29-fold increase compared with cells treated with ddhC^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.